Suggestions
Andrew Cavey
Healthcare executive
Andrew Cavey is a prominent professional in the pharmaceutical and biotechnology sectors, currently serving as the CEO of ITM Isotope Technologies Munich SE, a role he assumed on September 1, 2024. His career is marked by extensive experience in clinical development, corporate strategy, and commercial management within the industry.
Prior to joining ITM, Cavey held significant positions at Bristol Myers Squibb (BMS), where he was involved in key initiatives, including the acquisition of Mirati Therapeutics and the accelerated approval of lymphoma treatments by the U.S. FDA. His contributions have been recognized through various achievements and milestones in drug development and commercialization.
Cavey is active on LinkedIn, where he shares updates about his professional endeavors and industry developments. His profile reflects a commitment to advancing healthcare solutions through innovative radiopharmaceuticals and strategic corporate initiatives.
